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SPECIFIC AIMS
Our recent studies of experimental sepsis, induced by
cecal ligation and puncture (CLP) in rats, showed that
anti-C5a antibody protects against the lethal effects of
sepsis. The main aim of the current study was to obtain
maximally protective antibodies to rat C5a that would
protect in the CLP model and to determine to what
extent delayed treatment with anti-C5a would still af-
ford protection against sepsis-induced lethality.
PRINCIPAL FINDINGS
1. Antibodies to different peptide regions of rat C5a
have differential inhibitory activities on the functional
(chemotactic) activity of rat C5a
Rabbit polyclonal antibodies were developed to the
following peptide regions of rat C5a: amino-terminal
region (A), residues 1–16; middle region (M), residues
17–36; and the carboxyl-terminal region (C), residues
58–77 (Fig. 1). With the use of rat neutrophils, the
chemotactic activity of rat C5a was significantly inhib-
ited by antibodies with the following descending rank
order: anti-C . anti-M .. anti-A. The antibodies by
themselves did not evoke a significant response in rat
neutrophils.
2. The anti-C5a antibodies do not inhibit hemolytic
activity of rat serum
To assess to what extent anti-C5a preparations (anti-
C5a M or C) might interfere with the hemolytic activity
of rat serum (implying a blocking effect on the parent
molecule, C5) and assembly of C5b-9 (membrane at-
tack complex), whole hemolytic activity was measured
in presence or absence of these antibodies. There were
no significant differences in hemolysis of sensitized
sheep erythrocytes in the presence of fresh rat serum
containing preimmune IgG or anti-C5a M or C anti-
bodies, which suggests that these protective antibodies
do not block activation of the complement system.
3. Differential protective effects of C5a antibodies
during experimental sepsis
Our original studies of experimental sepsis (cecal liga-
tion and puncture in rats) showed that anti-C5a anti-
bodies could protect against the lethal effects of sepsis
(Czermak et al. Nature Medicine 5, 788–92, 1999). To
determine the targets on rat C5a that are most effective
for blockade, antibodies against A, M, and C peptides of
rat C5a (Fig. 1) or preimmune IgG were administered
immediately after the CLP procedure. The relative
protective efficacies (10-day survival rates of animals) of
anti-C5a preparations (in descending order of efficacy)
were anti-C . anti-M .. anti-A. Dose-dependent pro-
tective effects against the lethal complications of sepsis
in CLP animals was found when antibodies to the M or
C regions was used.
4. Anti-C5a M or C antibodies confer protective
effects during sepsis even after onset of symptoms of
sepsis
To determine if delayed infusion of antibodies could
still confer protective effects in vivo after CLP, 600 mg of
the most protective antibodies (anti-C5a M or C anti-
bodies) were intravenously infused 6, 12, or 24 h after
onset of CLP. When infused immediately after CLP (0
h, Fig. 2A), anti-C5a M or C-treated groups exhibited
highly protective effects (leading to 80% survival).
When infusion was delayed until 6 h after CLP (Fig.
2B), a time when clinical symptoms of sepsis were
evident, both antibodies still conferred significant pro-
tection. When infused 12 h after CLP, the majority of
animals exhibited typical clinical signs of sepsis: de-
creased physical activity, piloerection, cessation of
grooming behavior, glazed eyes with crusting exudates,
tachypnea, and reduced urinary output. Under these
conditions, infusion of anti-C5a M and anti-C5a C still
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significantly improved survival at 10 days (37% and
46%, respectively) as compared with the preimmune
IgG-treated group (12%) (Fig. 2C). The protective
effects of the anti-C5a M and C peptide antibodies were
lost, if infusion was delayed until 24 h after CLP (data
not shown). Although the anti-C5a protective effects
were diminished when delayed until late symptoms of
sepsis, these data suggest that delayed infusion of
anti-C5a, even in the presence of overt clinical signs of
sepsis, confers protective effects.
CONCLUSIONS
Abundant evidence suggests that homeostatic control
of the inflammatory system has been lost during sepsis,
as is reflected by cytokine and chemokine appearance
and unremitting data of complement activation. In
experimental sepsis induced by CLP, we have recently
demonstrated in rats that extensive complement activa-
tion occurs, which leads to C5a deposition on blood
neutrophils and a loss of the respiratory burst in these
cells and results in defective oxygen-dependent bacte-
rial killing and a high mortality rate. A rabbit polyclonal
antibody to the middle peptide region (M) of rat C5a
caused protective effects during sepsis. To establish the
most protective anti-C5a antibody preparation as well as
the dose of anti-C5a that provides optimal protection
against the lethal effects of sepsis, we raised polyclonal
antibodies against different peptide regions (A,M,C) of
the rat C5a molecule (Fig. 1). IgG antibodies targeting
the amino-terminal residues 1–16 (A region of C5a) did
not prevent the lethal consequences of experimental
sepsis, whereas antibodies against the middle core
residues 17–36 of the M region or against the carboxyl-
terminal residues 58–77 (C region) greatly improved
Figure 1. Location of se-
lected peptide regions for
antibody targeting (A 5
amino-terminal, M 5 mid-
dle peptide region and C 5
carboxy-terminal region),
based on the antigenic in-
dex and predicted molecu-
lar structure of C5a.
Figure 2. Ten-day survival rates of rats with sepsis; dependency
on the time of intravenous infusion of anti-C5a antibodies,
which were raised against the middle peptide region, residues
17–36 (anti-C5a M) or carboxyl-terminal region residues
58–77 (anti-C5a C). Animals received either 600 mg of
preimmune IgG or 600 mg anti-C5a M or C antibody imme-
diately after onset of CLP (A), 6 h after CLP (B), or 12 h after
CLP (C).
Figure 3. Schematic diagram of protective effects of anti-C5a administration from lethal consequences of sepsis.
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survival of CLP-rats in a dose dependent manner.
Although the amino-terminal region of C5a contributes
to the full potency of the intact C5a molecule and
serves to stabilize a biologically favorable C5a confor-
mation, blocking antibody to the amino terminal re-
gion (residues 1–16) was not an effective target, as
defined by lack of protective effects in CLP-induced
sepsis.
In the present study, antibodies against different
peptide regions of C5a suppressed the chemotactic
activity of rat neutrophils to rat C5a in a descending
order of potency: CMA, which mirrors the protective in
vivo effects of these antibodies. Because both recruit-
ment and activation of neutrophils during sepsis are
essential for local (e.g., peritoneal) remote organ (e.g.,
lung, liver, kidney) injury, effective blockade of anti-
C5a antibodies preserves vital protective functional
responses of neutrophils, especially the ability of these
cells to activate NADPH oxidase, result in less organ
injury and improved survival.
We have shown previously that injection of anti-C5a
immediately after sepsis-induction provides protection
against its detrimental effects. However, the present
data suggest that even after a considerable delay (6–12
h) in administering antibodies, which were targeted
against the M or C terminal regions of C5a, there was
still a significant improvement of survival (Fig. 2 and
Fig. 3). In the CLP model, relatively rapid development
of polymicrobial sepsis occurs within the first 12 h
resulting in lethal complications. The early events are
characterized by a hyperdynamic phase (2–10 h after
CLP), followed by a hypodynamic phase (after 16 h).
The hyperdynamic phase of sepsis is compressed in the
CLP model in rats into a rather brief period (16 h)
relative to that observed in humans, which often ap-
pears to extend over a three-day period. The data in the
rat model suggest that anti-C5a intervention is effective
during the hyperdynamic phase, although the protec-
tive effects diminish with time (Fig. 2). These data
suggest that, in humans with sepsis, there may be a
‘window’ of time of several days during which such an
intervention may be useful.
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